Lung Cancer

FDA Approves Subcutaneous Rybrevant Faspro for EGFR-Mutated Non-Small Cell Lung Cancer

Physician’s Briefing

FDA Approves Subcutaneous Rybrevant Faspro for EGFR-Mutated Non-Small Cell Lung Cancer

23 Dec 2025

1 min read

30-Year Smoking Duration-Based Criteria Could Increase Lung Cancer Screening

Physician’s Briefing

30-Year Smoking Duration-Based Criteria Could Increase Lung Cancer Screening

19 Dec 2025

2 min read

Guideline-Concordant Care Rate ~60 Percent After Positive Lung Cancer Screen in Seniors

Physician’s Briefing

Guideline-Concordant Care Rate ~60 Percent After Positive Lung Cancer Screen in Seniors

18 Dec 2025

2 min read

Read More

Clinical Briefing Report

clinicalbriefingreport.com